Abstract
Burning mouth syndrome (BMS) is a chronic orofacial pain condition that mainly affects postmenopausal women. BMS type I patients report little to no spontaneous pain in the morning and increases in pain through the day, peaking in the afternoon. Quantitative sensory testing (QST) findings from BMS type 1 patients are inconsistent as they fail to capture this temporal variation. We examined how QST in BMS type 1 compared to healthy participants was affected by time of day. QST of the face and forearm included warmth detection threshold (WDT), cold detection threshold (CDT), and heat pain thresholds (HPT), ratings of suprathreshold heat, and pressure pain thresholds (PPT), and was performed twice: once in the morning and once in the afternoon. BMS patients reported: no differences in morning and afternoon comparisons of the orofacial region between groups and no differences in PPTs in either orofacial or arm regions between groups; lower within group PPTs of the masseter in the afternoon; higher WDTs, and lower CDTs of the forearm in the morning compared to healthy participants; lower CDTs and higher pain intensity ratings to heat stimuli at low temperatures on the forearm in the afternoon compared to healthy participants. The findings indicate that compared to healthy participants, BMS Type I patients had altered thermal sensitivity, which depended on body area tested (forearm vs orofacial region), and higher pain sensitivity, which was slightly more pronounced in the afternoon plausibly due to a hypervigilance.
Perspective Somatosensory profiles in BMS type 1 can be affected by time of day, possibly as an effect of spontaneous burning pain that increases throughout the day. Our findings highlight the cyclical effect of BMS pathophysiology across a day, which may further help clinicians choose appropriate treatment strategies for BMS patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We would like to thank all our funding sources for making this work possible: NIDCR, NIH F31 DE027622-01A1, NIH 2T32NS063391-11A1, and NIGMS, NIH R25-GM55036 to JPS; NIDCR, NIH R21 DE023964-01A1 and 3R21DE023964-02S1 to DAS.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All research procedures were granted approval by the Institutional Review Board of the University of Maryland, Baltimore. Informed consent was obtained from each participant according to the Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing interests: The authors have no conflicts of interest to disclose.
Data Availability
N/A
